$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000162828021015392 Filed on August 03, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$15.35M	$21.68M
YoY Change	-29.2%	94.76%
Cost Of Revenue	$4.466M	$3.539M
YoY Change	26.19%	-34.7%
Gross Profit	$10.88M	$18.14M
YoY Change	-40.01%	217.67%
Gross Profit Margin	70.9%	83.67%
Selling, General & Admin	$13.13M	$13.89M
YoY Change	-5.47%	-14.48%
% of Gross Profit	120.73%	76.61%
Research & Development	$4.262M	$3.847M
YoY Change	10.79%	-52.8%
% of Gross Profit	39.18%	21.21%
Depreciation & Amortization	$728.0K	$700.0K
YoY Change	4.0%	-1.55%
% of Gross Profit	6.69%	3.86%
Operating Expenses	$17.40M	$17.74M
YoY Change	-1.94%	-40.5%
Operating Profit	-$6.517M	$395.0K
YoY Change	-1749.87%	-102.11%
Interest Expense	$2.757M	$2.747M
YoY Change	0.36%	41.82%
% of Operating Profit		695.44%
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.37M	-$2.334M
YoY Change	429.86%	-88.6%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.37M	-$2.334M
YoY Change	429.86%	-88.6%
Net Earnings / Revenue	-80.59%	-10.77%
Basic Earnings Per Share	-$0.33	-$0.07
Diluted Earnings Per Share	-$0.33	-$0.07
COMMON SHARES
Basic Shares Outstanding	37.07M shares	33.58M
Diluted Shares Outstanding	37.07M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$34.23M	$25.42M
YoY Change	34.67%	14.66%
Cash & Equivalents	$34.23M	$25.42M
Short-Term Investments
Other Short-Term Assets	$1.798M	$2.420M
YoY Change	-25.7%	15.24%
Inventory	$2.839M	$3.173M
Prepaid Expenses
Receivables	$12.13M	$12.89M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$51.00M	$43.91M
YoY Change	16.14%	12.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.791M	$8.457M
YoY Change	-31.52%	-22.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.908M	$289.0K
YoY Change	2290.31%	24.03%
Total Long-Term Assets	$15.88M	$19.64M
YoY Change	-19.15%	73.1%
TOTAL ASSETS
Total Short-Term Assets	$51.00M	$43.91M
Total Long-Term Assets	$15.88M	$19.64M
Total Assets	$66.88M	$63.55M
YoY Change	5.24%	26.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.100M	$8.787M
YoY Change	-7.82%	-56.14%
Accrued Expenses	$6.583M	$5.070M
YoY Change	29.84%	55.05%
Deferred Revenue	$642.0K	$803.0K
YoY Change	-20.05%	33.83%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.150M
YoY Change
Total Short-Term Liabilities	$23.04M	$14.88M
YoY Change	54.78%	-39.58%
LONG-TERM LIABILITIES
Long-Term Debt	$34.07M	$61.51M
YoY Change	-44.61%	31.21%
Other Long-Term Liabilities	$1.770M	$8.550M
YoY Change	-79.3%	140.85%
Total Long-Term Liabilities	$1.770M	$70.06M
YoY Change	-97.47%	38.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$23.04M	$14.88M
Total Long-Term Liabilities	$1.770M	$70.06M
Total Liabilities	$120.6M	$84.93M
YoY Change	42.04%	13.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$213.3M	-$149.3M
YoY Change	42.83%	50.2%
Common Stock	$39.00K	$34.00K
YoY Change	14.71%	36.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$53.77M	-$21.39M
YoY Change
Total Liabilities & Shareholders Equity	$66.88M	$63.55M
YoY Change	5.24%	26.06%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$12.37M	-$2.334M
YoY Change	429.86%	-88.6%
Depreciation, Depletion And Amortization	$728.0K	$700.0K
YoY Change	4.0%	-1.55%
Cash From Operating Activities	-$1.753M	-$9.990M
YoY Change	-82.45%	-41.82%
INVESTING ACTIVITIES
Capital Expenditures	-$197.0K	-$110.0K
YoY Change	79.09%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$197.0K	-$110.0K
YoY Change	79.09%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.687M	10.00K
YoY Change	86770.0%	-102.04%
NET CHANGE
Cash From Operating Activities	-1.753M	-9.990M
Cash From Investing Activities	-197.0K	-110.0K
Cash From Financing Activities	8.687M	10.00K
Net Change In Cash	6.737M	-10.09M
YoY Change	-166.77%	-43.22%
FREE CASH FLOW
Cash From Operating Activities	-$1.753M	-$9.990M
Capital Expenditures	-$197.0K	-$110.0K
Free Cash Flow	-$1.556M	-$9.880M
YoY Change	-84.25%	-42.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38599
	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
	dei	City Area Code CityAreaCode	908
	dei	Local Phone Number LocalPhoneNumber	941-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AQST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38886465	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34234000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31807000	USD
CY2021Q2	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12127000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	2839000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1798000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3402000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	50998000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	44625000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5791000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3102000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3448000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6908000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021Q2	us-gaap	Assets Assets	66875000	USD
CY2020Q4	us-gaap	Assets Assets	62884000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8100000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7089000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6583000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	823000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3633000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	693000	USD
CY2021Q2	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1737000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	728000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	642000	USD
CY2020Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1450000	USD
CY2021Q2	us-gaap	Loans Payable Current LoansPayableCurrent	5150000	USD
CY2020Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2575000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	23035000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21104000	USD
CY2021Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	34070000	USD
CY2020Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	34329000	USD
CY2021Q2	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	53003000	USD
CY2020Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	47524000	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2415000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2846000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6351000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1770000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1945000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	120644000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	111381000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38568242	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38568242	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34569254	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34569254	shares
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	39000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	35000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159488000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7921000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8201000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137725000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213296000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186257000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-53769000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66875000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62884000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21675000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30440000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4466000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3539000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7223000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7198000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4262000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3847000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13134000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13894000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26365000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28507000	USD
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	21862000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	21280000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	41509000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	43906000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6517000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	395000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15042000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13466000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	2757000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	2747000	USD
	us-gaap	Interest Expense InterestExpense	5518000	USD
	us-gaap	Interest Expense InterestExpense	5518000	USD
CY2021Q2	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3466000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18864000	USD
CY2020Q2	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	0	USD
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	6800000	USD
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	0	USD
CY2021Q2	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	373000	USD
CY2020Q2	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	18000	USD
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	321000	USD
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	120000	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12367000	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2334000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27039000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2334000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18864000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12367000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2334000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27039000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18864000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37065300	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33589174	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36318437	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33579434	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-53769000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-6122000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10197000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-306000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1507000	USD
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	27000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-51798000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9241000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-627000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	76000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1710000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-4000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1860000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1684000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3228000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3625000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-37000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-16530000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-20829000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	73000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1754000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-52000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2334000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-21388000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18864000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1497000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2388000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1167000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	6729000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	378000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	314000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-484000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	0	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	125000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	139000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5392000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-354000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2532000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6426000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1011000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3388000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2971000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-849000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2667000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15853000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23634000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	76000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	297000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	243000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-297000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-243000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18505000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	62000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	89000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18577000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2427000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23904000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49326000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34234000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25422000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3219000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4375000	USD
	aqst	Number Of Products Approved By Food And Drug Administration NumberOfProductsApprovedByFoodAndDrugAdministration	5	product
	us-gaap	Basis Of Accounting BasisOfAccounting	Basis of Presentation<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim unaudited condensed consolidated financial statements were prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) and with Article 10 of Regulation S-X for interim financial reporting. In compliance with those rules, certain information and footnote disclosures normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the fiscal year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 9, 2021 (the “2020 Annual Report on Form 10-K”). As included herein, the condensed consolidated balance sheet as of December 31, 2020 is derived from the audited consolidated financial statements as of that date. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results of interim periods have been included. The accompanying financial statements reflect certain reclassifications from previously issued financial statements to conform to the current presentation. The Company has evaluated subsequent events for disclosure through the date of issuance of the accompanying unaudited condensed financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reference in these notes to applicable guidance refers to the authoritative U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></div>
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34234000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213296000	USD
CY2021Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3177000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2021Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6993000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4326000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21675000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30440000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21675000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30440000	USD
CY2021Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9626000	USD
CY2020Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4330000	USD
CY2021Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3177000	USD
CY2020Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3081000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2021Q2	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	636000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	416000	USD
CY2021Q2	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12127000	USD
CY2020Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	6955000	USD
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	282000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	124000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	198000	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	2138000	USD
	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	4422000	USD
	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	3771000	USD
CY2021Q2	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	2789000	USD
	aqst	Accounts Receivable Allowances Provision Related To Sales AccountsReceivableAllowancesProvisionRelatedToSales	4422000	USD
CY2021Q2	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	636000	USD
CY2021Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2153000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	416000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1722000	USD
CY2021Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	811000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	789000	USD
CY2021Q2	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1130000	USD
CY2020Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1128000	USD
CY2021Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	898000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	544000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	2839000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2461000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44306000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	47751000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	38515000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	40878000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5791000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6873000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	728000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	700000	USD
	us-gaap	Depreciation Depreciation	1471000	USD
	us-gaap	Depreciation Depreciation	1414000	USD
CY2021Q2	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	430000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	863000	USD
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	235000	USD
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	377000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	819000	USD
CY2020Q2	us-gaap	Variable Lease Cost VariableLeaseCost	60000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	166000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	644000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1295000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	944000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	565000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	424000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4437000	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1199000	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3238000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2791000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2765000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	76000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	102000	USD
CY2021Q2	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	USD
CY2020Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	7000000	USD
CY2021Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	908000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	836000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6908000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	517000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7836000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	50000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	50000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4082000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6330000	USD
CY2021Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2153000	USD
CY2020Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	1722000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	348000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	2575000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	7725000	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6583000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8569000	USD
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	USD
	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	USD
CY2021Q2	us-gaap	Loans Payable Current LoansPayableCurrent	5150000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	12875000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	18025000	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10300000	USD
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	51500000	USD
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	USD
CY2020Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	48974000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	71000	USD
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	6729000	USD
CY2021Q2	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1737000	USD
CY2021Q2	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	54740000	USD
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37065300	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33589174	shares
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2334000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18864000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36318437	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33579434	shares
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1721000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1765000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3228000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3625000	USD
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1721000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1765000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3228000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3625000	USD
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	19270	shares
	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	14961	shares
	aqst	Stock Issued During Period Value Employee Stock Purchase Plans Discount StockIssuedDuringPeriodValueEmployeeStockPurchasePlansDiscount	11000	USD
	aqst	Stock Issued During Period Value Employee Stock Purchase Plans Discount StockIssuedDuringPeriodValueEmployeeStockPurchasePlansDiscount	11000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2334000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18864000	USD
CY2016Q3	aqst	Number Of States In The Antitrust Litigation NumberOfStatesInTheAntitrustLitigation	41	state

Files In Submission

Name	View Source	Status
0001628280-21-015392-index-headers.html	Edgar Link	pending
0001628280-21-015392-index.html	Edgar Link	pending
0001628280-21-015392.txt	Edgar Link	pending
0001628280-21-015392-xbrl.zip	Edgar Link	pending
aqst-06302021ex311.htm	Edgar Link	pending
aqst-06302021ex312.htm	Edgar Link	pending
aqst-06302021ex321.htm	Edgar Link	pending
aqst-06302021ex322.htm	Edgar Link	pending
aqst-20210630.htm	Edgar Link	pending
aqst-20210630.xsd	Edgar Link	pending
aqst-20210630_cal.xml	Edgar Link	unprocessable
aqst-20210630_def.xml	Edgar Link	unprocessable
aqst-20210630_htm.xml	Edgar Link	completed
aqst-20210630_lab.xml	Edgar Link	unprocessable
aqst-20210630_pre.xml	Edgar Link	unprocessable
etothemploymentagreement.htm	Edgar Link	pending
etothemploymentagreement001.jpg	Edgar Link	pending
etothemploymentagreement002.jpg	Edgar Link	pending
etothemploymentagreement003.jpg	Edgar Link	pending
etothemploymentagreement004.jpg	Edgar Link	pending
etothemploymentagreement005.jpg	Edgar Link	pending
etothemploymentagreement006.jpg	Edgar Link	pending
etothemploymentagreement007.jpg	Edgar Link	pending
etothemploymentagreement008.jpg	Edgar Link	pending
etothemploymentagreement009.jpg	Edgar Link	pending
etothemploymentagreement010.jpg	Edgar Link	pending
etothemploymentagreement011.jpg	Edgar Link	pending
etothemploymentagreement012.jpg	Edgar Link	pending
etothemploymentagreement013.jpg	Edgar Link	pending
etothemploymentagreement014.jpg	Edgar Link	pending
etothemploymentagreement015.jpg	Edgar Link	pending
etothemploymentagreement016.jpg	Edgar Link	pending
etothemploymentagreement017.jpg	Edgar Link	pending
etothemploymentagreement018.jpg	Edgar Link	pending
etothemploymentagreement019.jpg	Edgar Link	pending
etothemploymentagreement020.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2021 Q2 Form 10-Q Financial Statement

#000162828021015392 Filed on August 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2021 Q2 Form 10-Q Financial Statement

#000162828021015392 Filed on August 03, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst